EAGAN, Minn. , Nov. 10, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its third quarter ended September 30, 2022 , which continue to reflect revenue growth and increased gross profit margin as compared to prior year periods.
Leading authority on the therapeutic use of human tissues and cells EAGAN, Minn. , Oct. 25, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of David S. Smith , JD, to the company’s Board of Directors. Mr.
EAGAN, Minn. , Oct. 20, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of Raymond F. Vennare as Chief Executive Officer and Chairman of the Board, effective Nov. 1 . As an active member on the POAI Board of Directors since September 2021 and, as
EAGAN, Minn. , Sept. 19, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced several key developments to further strengthen the company’s offerings for pharmaceutical and biotech customers. First is Predictive Oncology’s Good Manufacturing Practices (GMP) lab, which opens
EAGAN, Minn. , Sept. 16, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced that J. Melville (“Mel”) Engle will retire as Chief Executive Officer and as Chairman and a member of the company’s Board of Directors. To ensure a smooth transition of his responsibilities, Mr.
EAGAN, Minn. , Aug. 11, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its second quarter ended June 30, 2022 , which shows a strong balance sheet with a solid cash balance, commensurate equity and no debt.
EAGAN, Minn. , July 26, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced a strategic move to further strengthen its business and product offerings by appointing Julia Kirshner , Ph.D., as Chief Scientific Officer. Dr. Kirshner currently serves as Senior Vice President at
EAGAN, Minn. , May 18, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has closed its
EAGAN, Minn. , May 16, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it has entered into
EAGAN, Minn. , May 12, 2022 (GLOBE NEWSWIRE) -- The financial results from the first quarter we believe depicts a solid potential for growth in the upcoming period, in accordance with the report by Predictive Oncology Inc. (NASDAQ: POAI) today, disclosing the results for the quarter ended March 31,
